欧州連合 - フランス語 - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, intestinale inflammatoire / antiinfective agents - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

欧州連合 - フランス語 - EMA (European Medicines Agency)

stada arzneimittel ag - tériparatide - ostéoporose - homéostasie du calcium - movymia est indiqué chez les adultes. traitement de l'ostéoporose chez les femmes ménopausées et chez les hommes à risque accru de fracture. chez les femmes ménopausées, une réduction significative de l'incidence des fractures vertébrales et non vertébrales, mais pas des fractures de la hanche, a été démontrée. le traitement de l'ostéoporose associée à une corticothérapie systémique chez les femmes et les hommes à risque accru de fractures..

欧州連合 - フランス語 - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophtalmologiques - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

欧州連合 - フランス語 - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agents antinéoplasiques - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. pour plus d'informations sur le statut du récepteur du facteur de croissance épidermique humain 2 (her2), veuillez vous référer à la section 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. pour plus d'informations sur le statut her2, veuillez vous référer à la section 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - omeprazolum - gélules gastro-résistantes - omeprazolum 20 mg, color.: e 104, excipiens de la capsule. - ulcustherapie, le syndrome de zollinger-ellison-syndrom - synthetika human

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - omeprazolum - gélules gastro-résistantes - omeprazolum 40 mg, color.: e 132, excipiens pro de la capsule. - ulcustherapie, le syndrome de zollinger-ellison-syndrom - synthetika human

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - omeprazolum - gélules gastro-résistantes - omeprazolum 10 mg, color.: e 104, excipiens de la capsule. - ulcustherapie, le syndrome de zollinger-ellison-syndrom - synthetika human

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - lisinoprilum - comprimés - lisinoprilum 5 mg à lisinoprilum dihydricum, excipiens pro compresso. - as-hemmer - synthetika

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - lisinoprilum - comprimés - lisinoprilum 10 mg à lisinoprilum dihydricum, excipiens pro compresso. - as-hemmer - synthetika

スイス - フランス語 - Swissmedic (Swiss Agency for Therapeutic Products)

spirig healthcare ag - lisinoprilum - comprimés - lisinoprilum 20 mg à lisinoprilum dihydricum, excipiens pro compresso. - as-hemmer - synthetika